Brief: Medicure receives response letter from FDA on Aggrastat SNDA for new indication

Medicure

08/07/2016 24:00

July 7 (Reuters) - Medicure Inc  MPH.V  
    * Medicure receives response letter from FDA on aggrastat 
SNDA for new indication 
    * Received a complete response letter from U.S. Food and 
Drug Administration (FDA) for its supplemental new drug 
application 
    * FDA does not approve application in its present form 
 
Source text for Eikon:  ID:nPn4Lqwg4a  
Further company coverage:  MPH.V  
 
 (Bengaluru Newsroom: +1-646-223-8780)